RE:dronabinol to germanyYes, okgonow is correct Keith said 2024 dronabinol shipments have exceeded 1.5m in revenue from multiple German pharmaceutical corps, he also said MPL's natural dronabinol is cheaper to produce with better stability than its peer synthetic version allowing MPL to sell it at attractive margins, .....Keith"we are preparing for future EPIDIOLEX generic launch for the US market...He also discussed the unique place MPL is in with potential DEA rescheduling, which he said could include strict NEW guidelines, and FDA oversight, ..,ONE of FEW GLOBALLY who've received FDA inspection/APPROVED facility for the cultivation of cannabis and derivative products and DEA import permits for cannabis products.....prepared remarks at the beginning touched on the signing of multiple agreements for B2B in Q4 for contract manufacturing for the Aussie and German market which could amount to 10m annualized revenues and ongoing negotiations for more"....also touched on managements belief MPL's share price is "significantly undervalued" when compared to its cash, assets, and competitors, which explanation.......please everyone if you haven't sign up and listen to the conference call...before the halt this afternoon ....IMO...started the call one hour early released the call within hours....obviously something very important/Last minute has arose for them to do this....VERY UNUSUAL.